Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Spalt-like transcription factor 2 (SALL2) is a **zinc finger transcription factor** in the Spalt-like family, conserved from nematodes to humans. It contains an N-terminal C2HC zinc finger domain, a glutamine-rich region, and several C2H2 zinc finger domains[1]. SALL2 controls key biological processes including neuronal differentiation, embryonic development, and regulation of cell migration through control of focal adhesion turnover and integrin β1 expression[1]. It exists as two main isoforms with tissue-specific functions. In development, SALL2 is expressed in the kidney, brain, and other tissues, but knockout studies in mice suggest it is not essential for embryonic or kidney development[2]. In cancer biology, SALL2 is regarded as a tumor suppressor in certain tissues, regulating the cell cycle and apoptosis, but acts as an oncogene in others. Its relevance for disease arises from its role in migration, cell cycle regulation, and differentiation; however, SALL2 is not currently a direct therapeutic target and no approved drugs are known to target this protein[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Spalt-like transcription factor 2 (SALL2).